CANNAINVESTOR Magazine June 2020 | Page 196

Q

A

CannaInvestor Magazine: What is your exit strategy?

Cannalogue: We’re planning to IPO in 24 to 36 months. However, we know that along the way we’ll be capturing value in a number of industries while disrupting others, thus a merger and acquisition is a possibility. We’re in the licensed producer space while disrupting big pharma. We’re in the healthcare technology and e-commerce spaces while functioning like a pharmaceutical distributor, thus providing a very attractive option to anyone who wants a global turn-key solution to participating in the medical cannabis or CBD sector.

Q

CannaInvestor Magazine: Why should investors invest in Cannalogue?

A

Cannalogue: Cannalogue is a physician-led platform that is a globally scalable and risk-mitigated spanning cannabis, technology, and healthcare. We were the first of our kind of licensing approved by Health Canada and the world’s first Shariah compliant medical cannabis company, something many thought would be impossible. Not only are we passionate about helping patients and disrupting the status quo with medical cannabis, we aim to revolutionize how we view mainstream medicine on a global scale.